How can we define a biomarker – Academic perspective – Nicola Normanno (INT-Fondazione Pascale, IT)

How can biomarkers have relevance to patients and health systems – Mark Lawler (Queen’s University Belfast, CDDF Board Member, UK)

Industry perspective, biomarkers & drug development – Ademi Santiago-Walker (Janssen R&D, US) – did not consent

Panel Discussion

Biomarkers and marketing authorisation of medicines in Europe – Olga Kholmanskikh (Famhp, BE) – did not consent

Biomarker-based drug development and authorisation in US – Reena Philip (FDA, US)

Biomarkers and HTA/PRA – does precision medicine lead to better access and reimbursement? – Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (CZ, NL) – did not consent

Panel Discussion

Precision oncology – What’s holding us back? – Peter Keeling (Diaceutics, IE)

Why patients want biomarkers – Warnyta Minnaard (Missie Tumor Onbekend, NL)

The Clinical consequences of not-testing – Rosa Giuliani (Guy’s and St Thomas’ NHS Foundation, UK)

Panel Discussion

Complete session

Challenges for biomarkers in clinical trials (patient selection, stratification, primary analysis) – Roberto Salgado (EORTC, BE)

IVDR implementation – industry perspective – Claudia Popp (Roche, CH)

IVDR implementation – regulatory perspective – Ana Trullas (EMA) & Olga Kholmanskikh (Famhp, BE) – did not consent

Panel Discussion